Lexaria Advances Oral Diabetes Treatment Study

Lexaria Bioscience (LEXX) has released an update.

Lexaria Bioscience Corp. is set to begin a human pilot study to test the oral delivery of tirzepatide, processed with their DehydraTECH technology, which has previously shown promise in improving absorption rates. The study aims to compare the effects of a single injected dose to daily oral dosing over a week in healthy volunteers. This innovative oral formulation could potentially transform the current injection-only administration of the diabetes medication that’s projected to generate significant revenue.

For further insights into LEXX stock, check out TipRanks’ Stock Analysis page.